Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowPfizer (PFE) trades at 8x forward earnings and has a 7% dividend yield, positioning it as a cheaper option compared to Amgen's (AMGN) 17x rebuild multiple. In Q1 2026, Pfizer's oncology franchise generated $3.83 billion in revenue, a 9% year-over-year increase, driven by its Seagen deal and Padcev, which contributed $591 million, up 39%. In contrast, Amgen's key products saw significant declines, with Prolia down 34% and Enbrel down 37%. This dissonance in performance highlights the contrasting strategies, where Pfizer is monetizing existing assets while Amgen is working on rebuilding growth, impacting investor sentiment toward both companies.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Amgen Inc. (AMGN)
Amgen is one of the world’s largest biotechnology companies.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier AMGN news
- Amgen (AMGN) Linked to 20 Deaths in Japan from Drug Usage
- Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning
- Amgen (AMGN) Reports 24% Growth Driven by Key Factors
- Amgen (AMGN) Q1 2026 Earnings Beat EPS Forecast
- Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
